# US 2025/0049914 A1 · Steroid acid-peptide based intracellular cargo delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049914 A1
- Document ID: US20250049914A1
- Status: Published application
- Kind: A1
- Application number: 18/717,506
- Filed: 2022-12-08
- Published: 2025-02-13
- Earliest claimed: 2021-12-08
- Assignees: Defence Therapeutics Inc.
- Applicants: Defence Therapeutics Inc.
- Inventors: Simon Beaudoin
- Web page: https://patentgrep.com/patent/US20250049914A1

## CPC

- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 39/0011: {Cancer antigens}
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 40/10: characterised by the cell type used
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61P 35/00: Antineoplastic agents
- C07K 14/005: from viruses
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 5/0669: {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N5/0647, C12N5/0663)}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/64: General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- C07K 2319/09: containing a nuclear localisation signal
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are compositions and methods relating to cargoes for improved intracellular delivery. The compositions generally comprise a steroid acid-peptide conjugate covalently linked to and/or admixed with a cargo to be delivered intracellularly to target cells, resulting in increased intracellular and/or cytosolic/nuclear delivery of the cargo, increased presentation of the cargo by target cells, increased intracellular reactive oxygen species production in target cells, and/or the transformation of immunosuppressive cells into immunostimulatory and/or proinflammatory cells. Methods of improving cargo stability via covalent conjugation with steroid acid-peptide moieties are also described herein, as well as the use of steroid acid-peptide conjugates for enhanced genome editing and in the production of cell-based vaccines.

## Claims

### Claim 1

A composition comprising a steroid acid-peptide conjugate covalently linked to and/or admixed with a cargo for intracellular delivery.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the cargo is or comprises a protein, peptide, polynucleotide, polynucleotide analog, polysaccharide, drug, or any combination thereof.

### Claim 3 (depends on 1, 2)

The composition of claim 1 or 2, wherein:
(a) the cargo does not bind specifically to a cell surface receptor or ligand;
(b) the cargo is not an antibody (e.g., an antibody that binds to a cell surface epitope);
(c) the cargo is not or does not comprise an antigen; or
(d) any combination of (a) to (c).

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1 to 3, wherein the cargo is or comprises a nuclease, such as a CRISPR-Cas nuclease (e.g., a class 2 CRISPR-Cas nuclease, such as Cas9 or Cas12a).

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1 to 4, wherein:
(a) covalently linking the cargo to the steroid acid-peptide conjugate increases intracellular delivery and/or cytosolic/nuclear delivery of the cargo, as compared to a corresponding composition lacking the steroid acid-peptide conjugate; or
(b) the cargo is admixed with a sufficient concentration of the steroid acid-peptide conjugate to increase intracellular delivery and/or cytosolic/nuclear delivery of the cargo, as compared to a corresponding composition lacking admixture with the steroid acid-peptide conjugate.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein the cargo is covalently linked to a sufficient number of steroid acid-peptide moieties such that the cargo exhibits greater stability (e.g., thermal stability) than the unmodified cargo.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6, wherein the steroid acid is or comprises a bile acid (e.g., a primary bile acid or a secondary bile acid).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1 to 7, wherein the steroid acid is or comprises:
(a) a bile acid which is: cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), glycodeoxycholic acid (GDCA), glycocholic acid (GCA), taurocholic acid (TCA), glycodeoxycholic acid (CDCA), glycochenodeoxycholic acid (GCDCA), taurodeoxycholic acid (TDCA), glycolithocholic acid (GLCA), taurolithocholic acid (TLCA), taurohyodeoxycholic acid (THDCA), taurochenodeoxycholic acid (TCDCA), ursocholic acid (UCA), tauroursodeoxycholic acid (TUDCA), ursodeoxycholic acid (UDCA), or glycoursodeoxycholic acid (GUDCA);
(b) an analog of the bile acid of (a) that: induces endocytosis; triggers ceramide accumulation on the inner leaflet of endosomes; triggers increased acid sphingomyelinase (ASM)-mediated cleavage of sphingomyelin to form ceramide; and/or has a hydrophobicity greater than that of cholic acid;
(c) a bile acid or bile acid analog that is more hydrophobic than cholic acid (e.g. CDCA, DCA, LCA, TCA, TDCA, TCDCA, GCA, GDCA, or GCDCA); or
(d) any combination of (a) to (c).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The composition of any one of claims 1 to 8, wherein each cargo molecule is covalently linked to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 steroid acid-peptide moieties.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The composition of any one of claims 1 to 9, wherein the steroid acid-peptide conjugate is covalently linked to the cargo via a cleavable or non-cleavable linker (e.g., bifunctional, trifunctional linker, or multi-functional linker).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The composition of any one of claims 1 to 10, wherein the steroid acid-peptide conjugate is covalently linked to the cargo via said peptide (e.g., the steroid acid is conjugated at or towards the N- or C-terminus of the peptide).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1 to 11, wherein the peptide:
(i) comprises a protein transduction domain that stimulates endocytosis and/or endosomal formation;
(ii) comprises a subcellular targeting signal;
(iii) is a cationic peptide (e.g., a non-cell-penetrating cationic peptide);
(iv) is a non-immunogenic peptide;
(v) comprises at least one cysteine residue (e.g., at or towards the peptide's N- and/or C terminus) having a free thiol group or a thiol group that is protected in a cleavable manner (e.g., by a pharmaceutically acceptable protecting group); or
(vi) any combination of (i) to (v).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The composition of any one of claims 1 to 12, wherein: the steroid acid is not or does not comprise cholic acid; the NLS peptide is not or does not comprise an SV40 NLS; and/or the steroid acid-peptide conjugate is not or does not comprise CA-SV40.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein the peptide is or comprises a nuclear localization signal which is a classical NLS (e.g., NLS from SV-40 large T-antigen (e.g., PKKKRKV; SEQ ID NO: 1 or 2) or from other classical NLSs) or a non-classical NLS (e.g., acidic M9 domain in the hnRNP A1 protein; the sequence KIPIK in yeast transcription repressor Matα2; PY-NLS; ribosomal NLS; and the complex signals of U snRNPs).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The composition of any one of claim 1 to 14, wherein the peptide is or comprises a nuclear localization signal which is a/an: SV40 NLS (e.g., comprised in SEQ ID NO: 1 or 2), GWG-SV40NLS (e.g., comprised in SEQ ID NO: 3), hnRNPA1 M9 NLS (e.g., comprised in SEQ ID NO: 4), hnRNP D NLS (e.g., comprised in SEQ ID NO: 5), hnRNP M NLS (e.g., comprised in SEQ ID NO: 6), PQBP-1 NLS (e.g., comprised in SEQ ID NO: 7), NLS2-RG Domain RPS17 (e.g., comprised in SEQ ID NO: 8), NLS1 RPS17 (e.g., comprised in SEQ ID NO: 9), NLS2 RPS17 (e.g., comprised in SEQ ID NO: 10), NLS3 RPS17 (e.g., comprised in SEQ ID NO: 11), cMyc NLS (e.g., comprised in SEQ ID NO: 12), HuR NLS (e.g., comprised in SEQ ID NO: 13), Tus NLS (e.g., comprised in SEQ ID NO: 14), or Nucleoplasmin NLS (e.g., comprised in SEQ ID NO: 15), or is a variant of an NLS having nuclear localization activity, the NLS comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 1 to 15.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The composition of any one of claims 1 to 15, wherein the steroid acid comprises CA or DCA, and the peptide comprises an hnRNPA1 M9 NLS or a variant thereof having nuclear localization activity.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The composition of any one of claim 1 to 16, wherein the peptide does not comprise an endosomal escape motif, or protein transduction motif, or cell penetrating motif.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The composition of any one of claims 1 to 17, wherein the composition or conjugate is formulated within a hydrogel, liposome, lipid-based transfection agent, or nanoparticle (e.g., lipid nanoparticle).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The composition of any one of claims 1 to 18, further comprising pharmaceutically or physiologically acceptable carrier and/or excipient.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1 to 19, for use in:
(a) increasing the intracellular, cytosolic, and/or nuclear delivery of a biologically active cargo (e.g., therapeutic cargo or diagnostic cargo) in vitro or in vivo, as compared to a corresponding composition lacking the steroid acid-peptide conjugate;
(b) increasing presentation of an antigenic polypeptide cargo by target cells, such as by professional anti-presenting cells (e.g., dendritic cells, macrophages, B cells, or non-immune cells engineered for overexpression of an immunoproteasome), or by non-professional antigen-presenting cells (e.g., wild-type, engineered, primary, and/or cultured non-immune cells, such as mesenchymal stromal cells (MCSs));
(c) increasing intracellular reactive oxygen species production in target cells, such as by professional anti-presenting cells (e.g., dendritic cells, macrophages, B cells, or non-immune cells engineered for overexpression of an immunoproteasome), or by non-professional antigen-presenting cells (e.g., wild-type, engineered, primary, and/or cultured non-immune cells, such as MCSs);
(d) transforming immunosuppressive cells (e.g., immunosuppressive MSCs) into immunostimulatory and/or proinflammatory MSCs; or
(e) any combination of (a) to (d).

### Claim 21 (depends on 20)

The composition for use of claim 20, wherein the composition is adapted or formulated for oral, intravenous, intranasal, intramuscular, subcutaneous, intradermal, intratumoral, intracranial, topical, intrarectal administration, or any other route of administration.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A method for delivering a cargo intracellularly, the method comprising providing a composition as defined in any one of claims 1 to 21, and administering the composition to target cells in vitro or in vivo.

### Claim 23

A method for preparing a cargo for intracellular delivery having increased stability, the method comprising covalently linking the cargo to a sufficient number of steroid acid-peptide moieties to produce a covalently-modified cargo that exhibits greater stability (e.g., thermal stability) than the corresponding unmodified cargo.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 23)

The method of claim 23, wherein the cargo and/or the steroid acid-peptide is as defined in any one of claims 1 to 17.

### Claim 25 (depends on 23, 24)

The method of claim 23 or 24, wherein the cargo is reacted or admixed with between a 2-fold and 1000-fold, 2-fold and 500-fold, 2-fold and 200-fold, 2-fold and 100-fold molar excess of the steroid acid-peptide conjugate; between a 2-fold and 50-fold molar excess of the steroid acid-peptide conjugate; or between a 5-fold and 25-fold molar excess of the steroid acid-peptide conjugate.

### Claim 26 (depends on 23, 24, 25)

The method of any one of claims 23 to 25, wherein the mean number of steroid acid-peptide moieties conjugated per cargo, or the molar ratio of cargo: steroid acid-peptide conjugate admixed, is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50; or wherein the mean number of steroid acid-peptide moieties conjugated per cargo is between about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 and n, wherein n is the total number of accessible sites on the cargo available for conjugation.

### Claim 27

A composition comprising an antigen covalently linked to and/or admixed with a steroid acid-peptide conjugate in an amount sufficient to improve presentation of the antigen upon administration of the composition to non-antigen presenting cells (e.g., mesenchymal stromal cells [MSCs]), as compared to administration of a corresponding composition lacking the steroid acid-peptide conjugate.

### Claim 28 (depends on 7, 8, 27)

The composition of claim 27, wherein the steroid acid or peptide is as defined in any one of claims 7, 8, or 10 to 17.

### Claim 29 (depends on 27, 28)

The composition of claim 27 or 28, wherein the molar ratio of steroid acid-peptide conjugate to antigen in the composition is at least 0.01:1, 0.05:1, 0.1:1, 0.2:1, 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1; is no more than 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 50:1, 100:1, 250:1, 500:1, 1000:1, and/or is between 1:1 to 1000:1; 1:1 to 500:1, 1:1 to 250:1, 1:1 to 200:1.

### Claim 30 (depends on 27, 28, 29)

The composition of any one of claims 27 to 29, wherein the steroid acid is conjugated to the peptide:
(a) at a molar ratio of steroid acid: peptide of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10:1, or between 1:1 to 10:1;
(b) at a free amino group and/or a free thiol group (e.g., of a lysine or cysteine) of the peptide;
(c) at or towards the N-terminal end of the peptide (e.g., at the free amino group of N terminal residue and/or at the thiol group of an N-terminal cysteine residue); or
(d) any combination of (a) to (c).

### Claim 31 (depends on 27, 28, 29, 30)

The composition of any one of claims 27 to 30, wherein the antigen is a polypeptide antigen comprising one or more MHC class I epitopes and/or MHC class II epitopes

### Claim 32 (depends on 27, 28, 29, 30, 31)

The composition of any one of claims 27 to 31, wherein the antigen is or comprises:
(a) a tumor-associated antigen (TAA), tumor-specific antigen (TSA), tumor lysate, a neoantigen, a viral antigen, a bacterial antigen, a fungal antigen, an antigen associated with a disease or disorder amenable to treatment by vaccination and/or immunotherapy; or any antigenic fragment thereof; or
(b) a corona viral antigen (e.g., SARS-CoV-2 Spike protein, SARS-CoV Spike protein, or an antigenic fragment thereof; or a cancer antigen, such as a single-nucleotide variant antigen, a mutational frameshift antigen, splice variant antigen, a gene fusion antigen, an endogenous retroelement antigen, or another class of antigen, such as a human leukocyte antigen (HLA)-somatic mutation-derived antigen or a post-translational TSA, a viral-derived cancer antigen (e.g., from human papillomavirus (HPV), cytomegalovirus, or Epstein-Barr virus (EBV)), a cancer-testis antigen, HER2, PSA, TRP-1, TRP-2, EpCAM, GPC3, CEA, MUC1, MAGE-A1, NY-ESO-1, SSX-2, mesothelin (MSLN), EGFR, cell lysates or other material derived from a tumor (e.g., tumor-derived exosomes).

### Claim 33 (depends on 27, 28, 29, 30, 31, 32)

The composition of any one of claims 27 to 32, further comprising a pharmaceutically acceptable excipient and/or adjuvant.

### Claim 34 (depends on 27, 28, 29, 30, 31, 32, 33)

A cell culture comprising non-antigen presenting cells (e.g., mesenchymal stromal cells [MSCs]) and the composition as defined in any one of claims 27 to 33.

### Claim 35

A cell culture comprising non-antigen presenting cells (e.g., mesenchymal stromal cells [MSCs]) pulsed with an antigen covalently linked to and/or admixed with a steroid acid-peptide conjugate.

### Claim 36 (depends on 27, 28, 29, 30, 31, 32, 34, 35)

A vaccine comprising the composition as defined in any one of claims 27 to 32, or comprising cells produced using the cell culture as defined in claim 34 or 35.

### Claim 37 (depends on 36)

The vaccine of claim 36, which is a therapeutic or prophylactic vaccine (e.g., anti-cancer vaccine, anti-viral vaccine, or anti-bacterial vaccine).

### Claim 38 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35)

A method for enhancing presentation of an antigen of interest in a subject or cells, the method comprising administering to the subject or in non-antigen presenting cells (e.g., mesenchymal stromal cells [MSCs]) the composition as defined in any one of claims 27 to 33, or cells produced using the cell culture as defined in claim 34 or 35.

### Claim 39 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35)

A method for vaccinating a subject against an infectious disease, the method comprising administering to the subject the composition as defined in any one of claims 27 to 33 or cells produced using the cell culture as defined in claim 34 or 35, wherein the antigen comprises an antigenic fragment of a pathogen (e.g., virus, bacteria, fungus) causing the infectious disease.

### Claim 40 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35)

A method for treating cancer in a subject, the method comprising administering to the subject the composition as defined in any one of claims 27 to 33 or cells produced using the cell culture as defined in claim 34 or 35, wherein the antigen is an overexpressed or aberrantly expressed in cells causing the cancer.

### Claim 41 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35)

The composition as defined in any one of claims 27 to 33, or the cell culture as defined in claim 34 or 35, for use in:
(i) generating enhancing presentation of an antigen of interest in a subject or in non-professional antigen presenting cells (e.g., mesenchymal stromal cells [MSCs]);
(ii) the manufacture of a medicament (e.g., vaccine) for generating an immune response in a subject;
(iii) increasing presentation of an antigenic polypeptide cargo by non-professional antigen-presenting cells (e.g., wild-type, engineered, primary, and/or cultured non-immune cells, such as mesenchymal stromal cells [MCSs]);
(iv) increasing intracellular reactive oxygen species production in by non-professional antigen-presenting cells (e.g., wild-type, engineered, primary, and/or cultured non-immune cells, such as MCSs);
(v) transforming immunosuppressive cells (e.g., immunosuppressive MSCs) into immunostimulatory and/or proinflammatory MSCs; or
(vi) any combination of (i) to (v).
